Evidence map›Paper›PMID 30630829›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

Mapping Physical Tumor Microenvironment and Drug Delivery.

Hadi T Nia, Lance L Munn, Rakesh K Jain

Abstract readComment
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Hydraulic conductivity of human cancer tissue: A hybrid study.Bioengineering & translational medicine · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Hadi T NiaEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Lance L MunnEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Rakesh K JainEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. jain@steele.mgh.harvard.edu.

Funding

Vascular Normalization: Rolse of Perivascular CellsP01CA080124 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2000 to 2016
$35.0M
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Benjamin Harris Kann · 2013 to 2026
$33.5M
AZD2171 and chemoradiation for newly diagnosed glioblastomaR01CA129371 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BATCHELOR, TRACY T · 2007 to 2017
$6.2M
Dissecting Pediatric Brain Tumor Microenvironment to Improve TreatmentR35CA197743 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2015 to 2020
$5.7M
Reprogramming PDAC tumor microenvironment to improve immunotherapyU01CA224348 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUCHER, YVES, JAIN, RAKESH K. · 2017 to 2021
$2.9M
Systems biology of lymphatic transportR01HL128168 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MUNN, LANCE L., PADERA, TIMOTHY P · 2015 to 2019
$2.9M
Targeting glycocalyx-mediated mechanisms of tumor metastasisR01CA204949 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI MUNN, LANCE L., TARBELL, JOHN M · 2017 to 2021
$2.3M
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatmentR01CA208205 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI, JAIN, RAKESH K. · 2017 to 2020
$2.2M
Alleviating solid stress to overcome immunotherapy resistance in metastatic breast cancerF32CA216944 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NIA, HADI TAVAKOLI · 2017 to 2018
$89k
NCI NIH HHS F32 CA216944NCI NIH HHS P01 CA080124NCI NIH HHS P50 CA165962NCI NIH HHS R01 CA129371NCI NIH HHS R01 CA204949NCI NIH HHS R01 CA208205NCI NIH HHS R35 CA197743NCI NIH HHS U01 CA224348NHLBI NIH HHS R01 HL128168
6 · The paper itself

Abstract

The physical microenvironment of pancreatic tumors is highly abnormal, and this causes significant challenges for drug delivery through multiple mechanisms. Measurements of tissue elasticity could be used as a physical biomarker to assess aberrant drug delivery, and potentially guide stroma-targeting treatment strategies and patient stratification.

Indexed as

Antineoplastic AgentsPancreatic NeoplasmsDrug Delivery SystemsHumansTumor MicroenvironmentAntineoplastic Agents

Identifiers

PMID30630829
PMCPMC6445672

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.